Diabetes mellitus, commonly referred to as diabetes, is the 8th leading cause of
death worldwide. As of 2015, approximately 415 million people were estimated to be diabetic
worldwide, type 2 diabetes being the most common accounting for approximately 90–95% of
all diagnosed cases with increasing prevalence. Fructose-1,6-bisphosphatase is one of the important
therapeutic targets recently discovered to treat this chronic disease. In this focused
review, we have highlighted recent advances and structure-activity relationship studies in the
discovery and development of different fructose-1,6-bisphosphatase inhibitors reported since
the year 2000.
Keywords: Fructose-1, 6-bisphosphatase Inhibitors, Type 2 diabetes, Adenosine 5’-monophosphate, Hyperglycemia, Diabetes mellitus.
Rights & PermissionsPrintExport